Hawthorn Pharmaceuticals cuts global deal with CoPlex
by MBJ Staff
Published: September 13,2011
MADISON — Hawthorn Pharmaceuticals Inc. has struck an exclusive global licensing deal with CoPlex Therapeutics on hawAD14, a preclinical oral small molecule candidate for the treatment of Alzheimer’s and other neurodegenerative diseases.
Under the terms of the agreement, Hawthorn will receive an exclusive worldwide license to develop and commercialize hawAD14 and will be responsible for funding all future development.
“In terms of the discovery’s uniqueness, it’s one of only few programs in the world demonstrating multiple protective effects against the predominant pathophysiologic pathways of Alzheimer’s disease,” said Rob Lewis, chief scientific officer at Hawthorn Pharmaceuticals.
“We are in the process of conducting the necessary preclinical studies in order to file an IND with the FDA,” said Max Draughn, Hawthorn Pharmaceuticals’ CEO.
To sign up for Mississippi Business Daily Updates, click here.
Top Posts & Pages
- Host families prepare for Mississippi Braves’ season
- Ridgeland property rights tussle is expected to have wide impact
- JOSH MABUS — Mississippi’s Healthcare: Not a quality problem, a marketing problem
- Mississippi takes an incentives licking, keeps on ticking
- PHIL HARDWICK: When will Mississippi change its culture?
- Investors in Northbrook complex say Ridgeland targeting its own collateral for demolition
- AWAITING ITS FATE: Gables complex may have to shrink to meet law
- HUNTER ARNOLD: Mississippi, Gulf Coast states focus on global business markets
- Bill would open hospital meetings, expand records access